Clyraguard
manufacturing and distribution through national partners begins
Westminster,
CA – October 8, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable
technologies and full-service environmental engineering company, today provided
highlights of its results and activities from the third quarter of 2020.
BioLargo
President & CEO Dennis P. Calvert commented, “With our subsidiary Clyra
Medical Technologies having successfully executed the first phase of the
Clyraguard product launch, this quarter set new records for BioLargo, and we expect
the next quarter to be even stronger for the company and Clyraguard. We have
made a significant investment in building our supply chain capabilities,
organizing our marketing team, and dedicated business development efforts, and we
expect future periods to continue to improve.”
Financial
highlights:
· BioLargo achieved record company-wide
revenue. Revenues for the period ended September 30, 2020 were approximately $650,000,
representing about a 60% increase compared to the $418,000 generated in the second
quarter of 2020. Revenues for the nine
months ended September 30, 2020 were approximately $1,600,000, about a 20%
increase compared to the $1,324,000 generated in the nine months ended September
30, 2019.
· Substantial improvements to the company’s
balance sheet, with $3,553,000 of debt being converted to equity by the company
since December 31, 2019.
Highlights
for BioLargo’s subsidiaries:
Clyra Medical Technologies
· Clyra is
executing on its comprehensive roll out plan for Clyraguard Personal Protective
Spray, having overcome early challenges developing a robust manufacturing and supply
chain during Covid. New manufacturing relationships support capacity of up to
1,000,000 Clyraguard units per month, and ample supply has been placed with
distributors across the country.
· Sales channels launching now include the largest distributors to the healthcare and restaurant
industries, Amazon.com, a revamped Clyraguard website (www.Clyraguard.com), and multiple online resellers, with a retail unit price of $25 per
bottle.
·
The Clyraguard launch is supported by new
company additions – Shawn Dougherty (Mophie founder), Johnny Sirpilla (former President
of Camping World), and new agreements with a national marketing and public
relations firm, and national sales organization, to be announced soon.
BioLargo
Engineering, Science & Technologies
· Multiple
projects are being finalized with two major municipal public water agencies for
the company’s PFAS treatment technology (the BioLargo AEC).
· Developed a proprietary and patent-pending
process to extract valuable mineral resources from a large industrial waste
site. As a consequence of this new process, a client is planning a substantial
long-term project expected to generate over $1B in revenues for the project. As
the client’s engineering services provider, and developer of the technology, BioLargo
Engineering is in discussions with the client to secure its role as the project
manager and/or lead engineer.
· Secured a
client contract for a project to use regenerative thermal oxidation for air
quality control (a particular expertise of some of our engineers), which is
expected to generate $500,000 in revenue for BioLargo Engineering through 2021.
· BioLargo
Engineering now has contracts in place for approximately $1,000,000 in revenue,
which is expected to be realized between now through the end of 2021.
ONM
Environmental
· Revenues
in the third quarter of 2020 began to rebound from their pandemic-related dip
to approximately $350,000.
· With nearly $400,000 in construction business
already secured for the fourth quarter of 2020,
management expects the fourth quarter 2020 to be a new high record for
revenue at ONM Environmental.
· Cannabusters (ONM Environmental’s white
label partner for the cannabis industry) is gaining traction in the market,
resulting in 12 equipment installations for ONM Environmental so far, with
another three contracted for the fourth quarter 2020.
BioLargo
Water
· BioLargo Water’s first commercial project
for its AOS water treatment technology, wherein the first for-profit
installation of an AOS will take place at a poultry farm, is moving forward as
planned, and which is expected to generate more than $500,000 in revenue over
the next year.
· Our
engineers are building the AOS unit to be installed at the wastewater treatment
facility near Montreal, Quebec, for the demonstration pilot to be run in
partnership with acclaimed water experts at the Centre des Technologies de
L’Eau (CTE).
· BioLargo
Water secured Health Canada approval for two hand sanitizer product
formulations and a license to manufacture and sell these products (one of which
incorporates CupriDyne technology), to serve its local community.
· Developed and
executed crucial EPA-approved protocols to produce data to support the efficacy
of a CupriDyne technology-related disinfectant in preparation for an EPA application
for a hard-surface disinfectant and sanitizer, in support of BioLargo’s efforts
to secure EPA registration.
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and
environmental engineering solutions provider driven by a mission to “make life
better”. We feature unique disruptive
solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which
eliminates the odor-causing compounds and VOCs rather than masking them, and is
now winning over leading companies in the solid waste handling and wastewater
industries and other industries that contend with malodors and VOCs. Our
subsidiary BioLargo Water (www.biolargowater.ca) develops
the Advanced Oxidation System "AOS," a disruptive industrial water
treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and technology
licensor to our subsidiary Clyra Medical which features its breakthrough
product Clyraguard (www.clyramedical.com/clyraguard), an FDA
Registered, hospital grade disinfectant for personal protective equipment
including facemasks, proven 99.999% effective and safe for skin, as well as its
other products offering gentle solutions for chronic infected wounds to promote
infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
During the course of the stockholder
presentation, BioLargo may make “forward-looking statements” within the meaning
of the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995, regarding future events or the future financial
performance of the company that are subject to change. Actual results may
differ from expectations, estimates and projections and, consequently, you should
not rely on these forward-looking statements as predictions of future events.
Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results
to differ materially from the expected results.
